340 related articles for article (PubMed ID: 29925295)
1. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
2. CD30 and ALK combination therapy has high therapeutic potency in RANBP2-ALK-rearranged epithelioid inflammatory myofibroblastic sarcoma.
Fordham AM; Xie J; Gifford AJ; Wadham C; Morgan LT; Mould EVA; Fadia M; Zhai L; Massudi H; Ali ZS; Marshall GM; Lukeis RE; Fletcher JI; MacKenzie KL; Trahair TN
Br J Cancer; 2020 Sep; 123(7):1101-1113. PubMed ID: 32684628
[TBL] [Abstract][Full Text] [Related]
3. Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring
Wang Z; Geng Y; Yuan LY; Wang MM; Ye CY; Sun L; Dai WP; Zang YS
Front Oncol; 2022; 12():761558. PubMed ID: 35237506
[TBL] [Abstract][Full Text] [Related]
4. Primary Cutaneous Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring RANBP2-ALK Fusion: Report of an Exceptional Case.
Gadeyne L; Creytens D; Dekeyser S; Van der Meulen J; Haspeslagh M
Am J Dermatopathol; 2022 Apr; 44(4):302-305. PubMed ID: 34816804
[TBL] [Abstract][Full Text] [Related]
5. Acquired resistance to crizotinib in novel CDK14-ALK and CLTC-ALK fusions of ALK-positive large B-cell lymphoma identified by next-generation sequencing.
Xia Y; Zhang L; He W; Pan H; Fang J; Cui G
Cancer Biol Ther; 2023 Dec; 24(1):2271212. PubMed ID: 37906510
[TBL] [Abstract][Full Text] [Related]
6. Pediatric Non-Myofibroblastic Primitive Spindle Cell Tumors with
Rakheja D; Park JY; Fernandes NJ; Watt TC; Laetsch TW; Collins RRJ
Int J Surg Pathol; 2022 Sep; 30(6):706-715. PubMed ID: 35164578
[TBL] [Abstract][Full Text] [Related]
7. Impact of ALK Inhibitors in Patients With
Takeyasu Y; Okuma HS; Kojima Y; Nishikawa T; Tanioka M; Sudo K; Shimoi T; Noguchi E; Arakawa A; Mori T; Sunami K; Kubo T; Kohno T; Akihiko Y; Yamamoto N; Yonemori K
JCO Precis Oncol; 2021; 5():. PubMed ID: 34036223
[TBL] [Abstract][Full Text] [Related]
8. Second Paediatric Strategy Forum for anaplastic lymphoma kinase (ALK) inhibition in paediatric malignancies: ACCELERATE in collaboration with the European Medicines Agency with the participation of the Food and Drug Administration.
Pearson ADJ; Barry E; Mossé YP; Ligas F; Bird N; de Rojas T; Zimmerman ZF; Wilner K; Woessmann W; Weiner S; Weigel B; Venkatramani R; Valteau D; Trahair T; Smith M; Singh S; Selvaggi G; Scobie N; Schleiermacher G; Richardson N; Park J; Nysom K; Norga K; Merino M; McDonough J; Matloub Y; Marshall LV; Lowe E; Lesa G; Irwin M; Karres D; Gajjar A; Doz F; Fox E; DuBois SG; Donoghue M; Casanova M; Caron H; Buenger V; Bradford D; Blanc P; Barone A; Reaman G; Vassal G
Eur J Cancer; 2021 Nov; 157():198-213. PubMed ID: 34536944
[TBL] [Abstract][Full Text] [Related]
9. Uterine Inflammatory Myofibroblastic Neoplasms With Aggressive Behavior, Including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases.
Collins K; Ramalingam P; Euscher ED; Reques Llanos A; García A; Malpica A
Am J Surg Pathol; 2022 Jan; 46(1):105-117. PubMed ID: 34138797
[TBL] [Abstract][Full Text] [Related]
10. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract][Full Text] [Related]
11. Epithelioid inflammatory myofibroblastic sarcoma with VCL-ALK fusion of central nervous system: case report and brief review of the literature.
Chopra S; Maloney N; Wang WL
Brain Tumor Pathol; 2022 Jan; 39(1):35-42. PubMed ID: 34743247
[TBL] [Abstract][Full Text] [Related]
12. Integration of Multi-omic Data in a Molecular Tumor Board Reveals EGFR-Associated ALK-Inhibitor Resistance in a Patient With Inflammatory Myofibroblastic Cancer.
Hunt AL; Nutcharoen A; Randall J; Papazian A; Deeken J; Maxwell GL; Bateman NW; Petricoin EF; Benyounes A; Conrads TP; Cannon TL
Oncologist; 2023 Aug; 28(8):730-736. PubMed ID: 37255276
[TBL] [Abstract][Full Text] [Related]
13. Leiomyoma-like Morphology in Metastatic Uterine Inflammatory Myofibroblastic Tumors.
Devins KM; Samore W; Nielsen GP; Deshpande V; Oliva E
Mod Pathol; 2023 Jun; 36(6):100143. PubMed ID: 36806735
[TBL] [Abstract][Full Text] [Related]
14. ALK-positive lung cancer in a patient with recurrent brain metastases and meningeal dissemination who achieved long-term survival of more than seven years with sequential treatment of five ALK-inhibitors: A case report.
Yamamoto K; Toyokawa G; Kozuma Y; Shoji F; Yamazaki K; Takeo S
Thorac Cancer; 2021 Jun; 12(11):1761-1764. PubMed ID: 33939293
[TBL] [Abstract][Full Text] [Related]
15. Update of Diagnosis and Targeted Therapy for ALK
Wang QA; Chen HW; Wu RC; Wu CE
Curr Treat Options Oncol; 2023 Dec; 24(12):1683-1702. PubMed ID: 37938503
[TBL] [Abstract][Full Text] [Related]
16. EML4-ALK fusion variant.3 and co-occurrent PIK3CA E542K mutation exhibiting primary resistance to three generations of ALK inhibitors.
Kunimasa K; Hirotsu Y; Kukita Y; Ueda Y; Sato Y; Kimura M; Otsuka T; Hamamoto Y; Tamiya M; Inoue T; Kawamura T; Nishino K; Amemiya K; Goto T; Mochizuki H; Honma K; Omata M; Kumagai T
Cancer Genet; 2021 Aug; 256-257():131-135. PubMed ID: 34130229
[TBL] [Abstract][Full Text] [Related]
17. Coexistence of a novel CCNY-ALK and ATIC-ALK double-fusion in one patient with ALK-positive NSCLC and response to crizotinib: a case report.
Wu X; Zhou H; He Z; Zhang Z; Feng W; Zhao J; Chen H; Wang S; Wang W; Wang Q
Transl Lung Cancer Res; 2020 Dec; 9(6):2494-2499. PubMed ID: 33489809
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathological features of inflammatory myofibroblastic tumor].
Zhu Y; Ding Y; Song GX; Li X; Ding R; Fan QH; Gong QX
Zhonghua Bing Li Xue Za Zhi; 2021 Mar; 50(3):194-200. PubMed ID: 33677881
[No Abstract] [Full Text] [Related]
19. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract][Full Text] [Related]
20. Exceptional response to the ALK and ROS1 inhibitor lorlatinib and subsequent mechanism of resistance in relapsed
Liu T; Merguerian MD; Rowe SP; Pratilas CA; Chen AR; Ladle BH
Cold Spring Harb Mol Case Stud; 2021 Aug; 7(4):. PubMed ID: 34210658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]